Gliknik

United States
Rosedale, Indiana, United States, 21201

Company profile

Gliknik company profile

Gliknik, Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders. Its Immunomodulator Platform involves in off-the-shelf peptide drugs that increase CD4, CD8, and antibody immune responses against cancer; Stradomer Platform produces drugs designed to mimic the eficacy of pooled human intravenous immunoglobulin; and Stradobody Platform produces compounds that are similar to moncolonal antibodies for tumor cell killing. The company was founded in 2007 and is based in Baltimore, Maryland.

Business identity

Phone number
(410) 685-0662
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2007-01-01, Year

Headquarters

Postal code
21201
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Late Stage Venture
Funding rounds
9
Total equity funding
$70.1M
Last funding
Series C / $11.5M / 2021-06-24
Last equity funding
Series C / $11.5M
Investors
5
Lead investors
3
Founders
2
Articles
16

Founders and investors

Founders

David S. BlockScott E. Strome

Lead investors

Baxter InternationalFirst In VenturesPfizer

Investors

Baxter InternationalFirst In VenturesJoel B. BraunsteinPfizerRDA Ventures